Inhibikase Therapeutics Announces Completion Of The 501 Bioequivalence Study Of IkT-001Pro
- 600 mg IkT-001Pro demonstrated bioequivalence to Standard-of-Care 400 mg Dose of Imatinib mesylate -
- Minimal adverse events with consistent drug delivery seen across 31 subjects in the pivotal trial -
-